Targeting the treatment of autoimmune diseases

A team of researchers from Charité – Universitätsmedizin Berlin and the Deutsches Rheuma-Forschungszentrum (DRFZ) Berlin, a Leibniz Institute, have successfully treated two patients with the autoimmune disease systemic lupus erythematosus. Using daratumumab, a monoclonal antibody which targets specific immune cells known as plasma cells, the researchers in the team of Tobias Alexander in collaobartion with Andreas Radbruch were able to modulate the abnormal immunological memory processes found in these patients. Treatment induced sustainable clinical responses and resulted in a reduction in systemic inflammation. The results of this research have been published in the New England Journal of Medicine*.

Please read more in the press relport of the Charité.